Linagliptina Medochemie

Linagliptin, the active ingredient in Linagliptina Medochemie, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adults and helps improve glycaemic control. GNH USA supplies Linagliptina Medochemie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to manage glucose levels in type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin. - Type 2 diabetes mellitus with renal impairment: provides effective glucose lowering without dose adjustment in patients with reduced kidney function.

Common Side Effects: - Nasopharyngitis: mild upper respiratory infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain. - Back pain: occasional musculoskeletal ache.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare autoimmune skin disorder.

Linagliptin should be used with clinical monitoring in several situations. - Renal impairment: no dose adjustment required, but monitor renal function regularly. - Hepatic impairment: use with caution and assess liver enzymes periodically. - Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas; educate patients on recognising low blood sugar. - Pancreatitis: discontinue if persistent severe abdominal pain occurs. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Linagliptin may interact with several medicines that affect glucose levels or drug metabolism. Major Interactions (Avoid): - Insulin: concurrent use can cause significant hypoglycaemia. - Sulfonylureas (e.g., glimepiride): increased risk of low blood glucose. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure. Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: monitor for angioedema, especially in patients with a history. - Diuretics: assess renal function and electrolytes. - Warfarin: check INR more frequently. - Digoxin: observe for any change in serum levels.